Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05664763 · ClinicalTrials.gov registry record · Early Phase 1
Understanding Effects of Cannabis Use and Abstinence on Neural Glutamate Homeostasis
A Early Phase 1 study, sponsored by Yale University.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 6
- Enrollment target
NCT05664763 is a Early Phase 1 study that was terminated before completion, run by Yale University. The registered enrollment target is 6 participants.
The verdict
NCT05664763, a Early Phase 1 study, was terminated before completion, sponsored by Yale University.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
This study will be the first in vivo human multimodal neuroimaging study exploring the relationship between mGluR5 availability (PET), neural oscillations (EEG), and cognitive function in people with CUD. The goal is to test the overall hypothesis that mGluR5 availability is higher in people with CUD compared with HC. In Aim 1, the investigators will determine differences in mGluR5 availability between people with CUD and HC in the fronto-limbic brain circuit. Aim 2 examines the associations between mGluR5 availability, CUD severity, neural oscillations, and cognitive function in CUD subjects. Aim 3 will determine how prolonged abstinence from chronic cannabis use affects mGluR5 availability, neural oscillations, and cognitive function in CUD subjects.
Interventions
- DRUG [18F]FPEB with PET
- BEHAVIORAL Cannabis abstinence
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2023-03-01 |
| Est. Completion | 2024-07-03 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05664763
The ClinicalTrials.gov registry entry for NCT05664763 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which [18F]FPEB with PET is the first listed.
NCT05664763 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05664763 about?
NCT05664763 is a clinical study titled "Understanding Effects of Cannabis Use and Abstinence on Neural Glutamate Homeostasis". This study will be the first in vivo human multimodal neuroimaging study exploring the relationship between mGluR5 availability (PET), neural oscillations (EEG), and cognitive function in people with CUD. The goal is to test the overall hypothesis that mGluR5 availability is higher in people with CU...
What is the current status of trial NCT05664763?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 6 participants. The study started on 2023-03-01. Estimated completion is 2024-07-03.
What interventions are being tested in trial NCT05664763?
The interventions under investigation include: [18F]FPEB with PET (DRUG), Cannabis abstinence (BEHAVIORAL).
Who is sponsoring clinical trial NCT05664763?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.